Objectives: This study investigated a cluster of secondary human-to-human transmission of severe fever with thrombocytopenia syndrome (SFTS) in a hospital setting, focusing on infection risk factors and the role of personal protective equipment (PPE). Methods: A descriptive epidemiological investigation was conducted following the death of anindex patient with laboratory-confirmed SFTS. A total of 27 close contacts, including healthcareworkers and a funeral director, were monitored for symptoms. Suspected cases underwent real-time reverse transcription polymerase chain reaction testing. Clinical features, PPE use, and exposure histories were analyzed. The Fisher exact test was used to assess associations between PPE use and infection. Viral genotyping and sequence analyses were performed to evaluate transmission routes. Results: The index patient deteriorated rapidly and died after repeated cardiopulmonaryresuscitation (CPR), during which 8 secondary cases occurred. Most infections were identifiedamong individuals involved in CPR or postmortem care without adequate PPE. Although notstatistically significant, infection rates were higher among those who did not wear masks or who used low-filtration masks. Proper use of gloves, gowns, and goggles was associated withlower infection rates. Cycle threshold values in secondary cases (range, 34–39) were higherthan in the index case (14.07), suggesting lower viral loads. Sequence analysis demonstrated99.6%–100% homology between the index and secondary cases; all isolates were genotype B, indicating direct transmission. Conclusion This study provides molecular and epidemiological evidence of nosocomial SFTS transmission. Inadequate PPE use during aerosol-generating procedures likely facilitated infection, underscoring the importance of strict adherence to PPE protocols and reinforced infection control practices.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Purpose: This study aimed to systematically evaluate school-based suicide prevention programs for adolescents, focusing on their impact on suicide attempts, knowledge and attitudes about suicide, and help-seeking behaviors. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Cochrane Library, EMBASE, PsycINFO, CINAHL, KMBASE, KoreaMed, and ScienceON. Randomized controlled trials of school-based interventions for middle and high school students were included. The Risk of Bias 2.0 tool was used to assess study quality. Results: Out of 1,738 screened records, eight studies met the inclusion criteria. SOS (Signs of Suicide) and SEYLE (Saving and Empowering Young Lives in Europe) programs significantly reduced suicide attempts by 40% and 55%, respectively. Sources of Strength improved help-seeking behavior (ES=0.62, p<.001), though results were inconsistent across interventions. All programs enhanced knowledge and attitudes about suicide, but methodological limitations, such as variability in implementation and reporting, affected reliability. Conclusion School-based suicide prevention programs effectively reduce suicide attempts and improve awareness but show mixed results for help-seeking behaviors. Standardized, scalable interventions and rigorous evaluations are needed to enhance their impact.

Purpose: This study aimed to systematically evaluate school-based suicide prevention programs for adolescents, focusing on their impact on suicide attempts, knowledge and attitudes about suicide, and help-seeking behaviors. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Cochrane Library, EMBASE, PsycINFO, CINAHL, KMBASE, KoreaMed, and ScienceON. Randomized controlled trials of school-based interventions for middle and high school students were included. The Risk of Bias 2.0 tool was used to assess study quality. Results: Out of 1,738 screened records, eight studies met the inclusion criteria. SOS (Signs of Suicide) and SEYLE (Saving and Empowering Young Lives in Europe) programs significantly reduced suicide attempts by 40% and 55%, respectively. Sources of Strength improved help-seeking behavior (ES=0.62, p<.001), though results were inconsistent across interventions. All programs enhanced knowledge and attitudes about suicide, but methodological limitations, such as variability in implementation and reporting, affected reliability. Conclusion School-based suicide prevention programs effectively reduce suicide attempts and improve awareness but show mixed results for help-seeking behaviors. Standardized, scalable interventions and rigorous evaluations are needed to enhance their impact.

Purpose: This study aimed to systematically evaluate school-based suicide prevention programs for adolescents, focusing on their impact on suicide attempts, knowledge and attitudes about suicide, and help-seeking behaviors. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Cochrane Library, EMBASE, PsycINFO, CINAHL, KMBASE, KoreaMed, and ScienceON. Randomized controlled trials of school-based interventions for middle and high school students were included. The Risk of Bias 2.0 tool was used to assess study quality. Results: Out of 1,738 screened records, eight studies met the inclusion criteria. SOS (Signs of Suicide) and SEYLE (Saving and Empowering Young Lives in Europe) programs significantly reduced suicide attempts by 40% and 55%, respectively. Sources of Strength improved help-seeking behavior (ES=0.62, p<.001), though results were inconsistent across interventions. All programs enhanced knowledge and attitudes about suicide, but methodological limitations, such as variability in implementation and reporting, affected reliability. Conclusion School-based suicide prevention programs effectively reduce suicide attempts and improve awareness but show mixed results for help-seeking behaviors. Standardized, scalable interventions and rigorous evaluations are needed to enhance their impact.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Purpose: This study aimed to systematically evaluate school-based suicide prevention programs for adolescents, focusing on their impact on suicide attempts, knowledge and attitudes about suicide, and help-seeking behaviors. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Cochrane Library, EMBASE, PsycINFO, CINAHL, KMBASE, KoreaMed, and ScienceON. Randomized controlled trials of school-based interventions for middle and high school students were included. The Risk of Bias 2.0 tool was used to assess study quality. Results: Out of 1,738 screened records, eight studies met the inclusion criteria. SOS (Signs of Suicide) and SEYLE (Saving and Empowering Young Lives in Europe) programs significantly reduced suicide attempts by 40% and 55%, respectively. Sources of Strength improved help-seeking behavior (ES=0.62, p<.001), though results were inconsistent across interventions. All programs enhanced knowledge and attitudes about suicide, but methodological limitations, such as variability in implementation and reporting, affected reliability. Conclusion School-based suicide prevention programs effectively reduce suicide attempts and improve awareness but show mixed results for help-seeking behaviors. Standardized, scalable interventions and rigorous evaluations are needed to enhance their impact.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.